Alimera Sciences (NASDAQ:ALIM) Research Coverage Started at StockNews.com

Research analysts at StockNews.com began coverage on shares of Alimera Sciences (NASDAQ:ALIM) in a research report issued on Monday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

A number of other research analysts have also issued reports on ALIM. Maxim Group reaffirmed a “hold” rating on shares of Alimera Sciences in a report on Tuesday, June 25th. Alliance Global Partners reissued a “neutral” rating on shares of Alimera Sciences in a research note on Tuesday, June 25th. Finally, HC Wainwright cut Alimera Sciences from a “buy” rating to a “neutral” rating and set a $6.00 target price on the stock. in a research note on Tuesday, June 25th.

Alimera Sciences Price Performance

Shares of NASDAQ ALIM opened at $5.54 on Monday. Alimera Sciences has a fifty-two week low of $2.61 and a fifty-two week high of $5.65. The firm’s 50-day simple moving average is $5.55 and its 200 day simple moving average is $4.51. The company has a quick ratio of 2.62, a current ratio of 2.79 and a debt-to-equity ratio of 1.80. The stock has a market cap of $290.24 million, a P/E ratio of -3.53 and a beta of 1.25.

Alimera Sciences (NASDAQ:ALIM) last issued its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02). The company had revenue of $27.00 million for the quarter, compared to the consensus estimate of $25.76 million. Alimera Sciences had a negative net margin of 14.74% and a negative return on equity of 33.70%. Equities analysts expect that Alimera Sciences will post -0.13 EPS for the current year.

Institutional Investors Weigh In On Alimera Sciences

Institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. boosted its position in shares of Alimera Sciences by 61.1% in the first quarter. Vanguard Group Inc. now owns 1,045,460 shares of the biopharmaceutical company’s stock valued at $4,077,000 after acquiring an additional 396,506 shares during the period. Glazer Capital LLC bought a new stake in shares of Alimera Sciences in the second quarter valued at approximately $3,067,000. Ancora Advisors LLC bought a new stake in shares of Alimera Sciences in the first quarter valued at approximately $915,000. Renaissance Technologies LLC raised its stake in shares of Alimera Sciences by 3.9% in the second quarter. Renaissance Technologies LLC now owns 181,694 shares of the biopharmaceutical company’s stock valued at $1,010,000 after purchasing an additional 6,900 shares in the last quarter. Finally, Deltec Asset Management LLC acquired a new position in shares of Alimera Sciences in the second quarter valued at $690,000. 99.83% of the stock is currently owned by institutional investors and hedge funds.

Alimera Sciences Company Profile

Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).